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Abstract: Post-traumatic stress disorder (PTSD) is a severe psychiatric illness that disproportionately
affects military personnel, veterans, and public safety personnel (PSP). Evidence demonstrates
that PTSD is significantly associated with difficulties with emotion regulation (ER) and difficulties
with cognitive functioning, including difficulties with attention, working memory, and executive
functioning. A wide body of evidence suggests a dynamic interplay among cognitive dysfunction,
difficulties with ER, and symptoms of PTSD, where numerous studies have identified overlapping
patterns of alterations in activation among neuroanatomical regions and neural circuitry. Little work
has examined interventions that may target these symptoms collectively. The primary objective
of this pilot randomized controlled trial (RCT) with a parallel experimental design was to assess
the effectiveness of goal management training (GMT), a cognitive remediation intervention, in
reducing difficulties with cognitive functioning, and to determine its effects on PTSD symptoms and
symptoms associated with PTSD, including difficulties with ER, dissociation, and functioning among
military personnel, veterans, and PSP. Forty-two military personnel, veterans, and PSP between
the ages of 18 and 70 with symptoms of PTSD were recruited across Ontario, Canada between
October 2017 and August 2019. Participants were randomized to either the waitlist (WL) (n = 18)
or the GMT (n = 22) condition. Participants in both conditions received self-report measures and a
comprehensive neuropsychological assessment at baseline, post-intervention, and 3-month followup. Following their completion of the 3-month follow-up, participants in the WL condition were
given the opportunity to participate in GMT. Assessors and participants were blind to intervention
allocation during the initial assessment. A series of 2 (time) × 2 (group) ANOVAs were conducted to
assess the differences between the WL and GMT conditions from pre- to post-intervention for the
self-report and neuropsychological measures. The results demonstrated significant improvements
in measures of executive functioning (e.g., verbal fluency, planning, impulsivity, cognitive shifting,
and discrimination of targets) and trending improvements in short-term declarative memory for
participants in the GMT condition. Participants in the GMT condition also demonstrated significant
improvements from pre- to post-testing in measures of subjective cognition, functioning, PTSD
symptom severity, difficulties with ER, dissociative symptom severity, and depression and anxiety
symptoms. No adverse effects were reported as a result of participating in GMT. The results of this
pilot RCT show promise that GMT may be a useful intervention to improve symptoms of cognitive
dysfunction, symptoms of PTSD, and symptoms associated with PTSD within military personnel,
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veterans, and PSP. Future work is needed to address the small sample size and the durability of
these findings.
Keywords: cognitive dysfunction; cognitive remediation; emotion regulation; goal management
training; military; posttraumatic stress disorder; public safety personnel; veterans

1. Introduction
Post-traumatic stress disorder (PTSD) is a severe psychiatric illness that occurs as a
result of experiencing, witnessing, or learning about a traumatic event or events [1]. Military personnel, veterans, and public safety personnel (PSP) (i.e., dispatchers, correctional
workers, police officers, firefighters, paramedics, and emergency medical technicians) [2]
are regularly exposed to potentially traumatic events, such as natural disasters, military
conflicts, motor vehicle accidents, assaults, and death, due to the nature of their work [3],
placing these individuals at increased risk for the development of PTSD relative to the
general population [3–5]. Here, compared to Canadian civilians, where approximately
9% meet the criteria for lifetime prevalence of PTSD [6], the lifetime prevalence of PTSD
within Canadian military personnel and veterans is estimated to be 22% [7]. Although
no lifetime prevalence estimates of PTSD currently exist for PSP, approximately 23% of
PSP met the diagnostic criteria of PTSD within the past month when assessed using a
web-based self-report survey [3].
According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) [1], PTSD is characterized by re-experiencing symptoms (e.g., intrusive and
distressing memories, dreams, or flashbacks), avoidance, alterations in mood and thoughts
(e.g., negative beliefs about oneself, others, the world; persistent low mood or anhedonia),
and changes in arousal (e.g., hypervigilance, angry outbursts). Individuals with PTSD may
also experience symptoms of dissociation associated with feelings of derealization (i.e.,
feeling as though the world around oneself is unreal or strange) or depersonalization (i.e.,
perception of the self feels unreal or strange) and may be diagnosed with the dissociative
subtype of PTSD [1]. Notably, approximately 16% to 19% of veterans diagnosed with PTSD
meet the criteria for this subtype [8].
PTSD is also comorbid with several other psychiatric disorders, including major
depressive disorder (MDD) [1,6,9], anxiety disorders [1,9], and alcohol and substance use
disorders [1,6,9]. For example, among a Canadian military personnel and veteran sample
diagnosed with PTSD during their lifetime, approximately 80% also had a comorbid
diagnosis of MDD, 59% had a comorbid diagnosis of social anxiety disorder, 51% had a
comorbid diagnosis of panic disorder, and 46% had a comorbid diagnosis of generalized
anxiety disorder [7].
Critically, PTSD is highly associated with difficulties with emotion regulation (ER), a
transdiagnostic factor across various psychiatric conditions that refers to difficulties with
moderating and managing emotions [10–19]. Here, elevated levels of difficulties with
ER are associated with increased PTSD symptom severity and expression [13,14,16,18,19].
Moreover, symptoms of dissociation associated with PTSD may serve as a form of ER
strategy, allowing individuals to disengage from experiencing highly distressing emotions [15]. Together, these findings suggest that difficulties with ER may contribute to PTSD
symptom maintenance and point towards the need for targeted treatment approaches for
the resolution of ER difficulties among individuals with PTSD [20]. Despite this knowledge,
to date, systematic approaches for the treatment of ER difficulties are seldom employed in
the treatment of PTSD, instead forming a relatively small component of more cognitively
oriented approaches such as cognitive processing therapy [21,22] and prolonged exposure
therapy [23].
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Along with other neuropsychiatric presentations, such as MDD and anxiety disorders,
PTSD is also associated with difficulties in cognitive functioning [1,24]. Here, negative
alterations in verbal learning, declarative memory [25–28], attention, working memory, executive functioning [26,29–32], and processing speed [26,28] are routinely observed among
individuals with PTSD. Data from a meta-analysis have demonstrated medium effect size
impairments associated with PTSD occurring in verbal learning (Cohen’s d = −0.62), processing speed (Cohen’s d = −0.59), and attention and working memory (Cohen’s d = −0.50),
with executive functioning (Cohen’s d = −0.45), verbal memory (Cohen’s d = −0.46), language (Cohen’s d = −0.43), visuospatial functioning (Cohen’s d = −0.38), visual learning
(Cohen’s d = −0.32), and visual memory (Cohen’s d = −0.29) demonstrating smaller effect
sizes [28]. Notably, this meta-analysis found an overall medium effect size impairment
of PTSD on neurocognitive functioning (Cohen’s d = −0.49). In another meta-analysis,
the researchers compared executive functioning in a PTSD group to healthy and traumaexposed control groups [32]. Here, it was found that individuals in the PTSD group demonstrated small to moderate impairments in executive functioning (i.e., Hedges’ g = 0.464 and
Hedges’ g = 0.414 for the healthy and trauma-exposed control groups, respectfully), independent of PTSD symptom severity, suggesting that difficulties with executive functioning
may be present across varying levels of PTSD symptom severity. These findings also align
with previous meta-analysis results [28].
Additional work has explored cognitive difficulties among individuals with PTSD
and comorbid dissociative symptoms [33–35]. Here, it has been found that there are negative alterations in verbal and visual memory [34], attention, executive functioning, and
autobiographical memory [35] among individuals with PTSD and co-occurring dissociative
symptoms. In conjunction with these objective cognitive difficulties, individuals with
PTSD also report subjective difficulties with cognitive functioning [36,37], which are associated with increased psychological symptom severity among military veterans [38] and
civilians [39].
Cognitive dysfunction also is associated with negative impacts on physical [40], social,
and occupational functioning (e.g., increased absenteeism) [40,41], as well as poorer psychological treatment outcomes, among military personnel and civilians with PTSD [42–45].
These difficulties may be long-standing, where alterations in cognitive performance continue to persist in approximately 25% of individuals who have completed either cognitive
processing therapy or prolonged exposure therapy [46]. Like difficulties in ER, however,
negative alterations in cognitive functioning (i.e., both objective and subjective difficulties)
are rarely addressed as a specific treatment target in PTSD, despite their associations with
poorer outcomes and increased symptom severity [36].
Importantly, a wide body of evidence suggests a dynamic interplay among cognitive dysfunction, difficulties with ER, and symptoms of PTSD, where numerous studies
have identified overlapping patterns of alterations in activation among neuroanatomical
regions [15,47–53] and large-scale neural circuitry [54–57]. Here, reductions in activation of
pre-frontal cortical regions, such as the medial pre-frontal cortex and the rostral anterior
cingulate cortex, have been associated with decreases in top-down control of emotion
processing and regulation centres of the brain, such as the amygdala and other limbic
regions [15,50,51]. Conversely, increases in activation of pre-frontal cortical regions have
been associated with increases in top-down control of emotion processing and regulation
centres of the brain. This profile of hypoactivation of pre-frontal cortical regions and
concomitant hyperactivation of emotion processing and regulation centres of the brain
is thought to contribute to emotional undermodulation and associated re-experiencing
and hyperarousal symptoms among individuals with PTSD [15,50]. Comparatively, hyperactivation of pre-frontal cortical regions and concomitant hypoactivation of emotion
processing and regulation centres of the brain contribute to emotional overmodulation,
which is associated with symptoms of dissociation. Critically, many of these same prefrontal cortical regions are associated with higher-order cognitive functioning, including
executive functioning, working memory, and attentional control [58,59], with alterations
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in neural activity thought to underlie, in part, alterations in cognitive functioning among
individuals with PTSD [26,29–32].
These neuroanatomical regions form larger brain networks, including the default
mode network (DMN), the central executive network (CEN), and the salience network
(SN) [60–62]. In the absence of any significant dysfunction, these neurocognitive networks
work in conjunction with one another and are responsible for the top-down control of
various processes, including cognitive functioning, emotions, and ER. Specifically, the DMN
is associated with self-referential mental activity, such as self-monitoring, autobiographical
memory, and future- or past-oriented thinking [61,63]. It is typically activated during
rest and deactivated during cognitive tasks. Moreover, the DMN is anchored within
the posterior cingulate cortex, the medial pre-frontal cortex, and the medial temporal
lobe [61]. The CEN contributes to executive functioning, attention, memory, goal-directed
behaviours, and the cognitive control of emotions and ER. It includes nodes in the precuneus, dorsolateral pre-frontal cortex, and lateral posterior parietal cortex [60,61,64].
Finally, the SN is involved with directing attention to relevant internal and external stimuli
and is co-activated with the CEN during cognitive tasks [60]. It is associated with nodes
within the amygdala, anterior cingulate cortex, and anterior insula [60,61].
Like the evidence demonstrating differences in neural activity amongst the different brain regions in individuals with PTSD and its dissociative subtype [15,50], evidence
demonstrates that these neural networks show aberrant patterns of connectivity at rest
and during symptom provocation [56,65–73]. Generally, findings have shown patterns of
hypoconnectivity within the DMN [55,74–76], hypoconnectivity between the DMN and the
CEN [54–56,74,76,77], hypoconnectivity within the CEN [55,56,75], and hyperconnectivity
within the SN [54–56]. Critically, these patterns of connectivity are associated with symptoms of PTSD, including symptoms of dissociation, avoidance, re-experiencing symptoms,
a reduced ability to switch between task-relevant and task-irrelevant behaviours, cognitive deficits, hypervigilance, and fear [54–56,70]. Moreover, evidence has demonstrated
differential patterns of neural connectivity among individuals with PTSD, individuals
with the dissociative subtype of PTSD, and healthy controls [70]. For example, among
individuals with the dissociative subtype of PTSD, Nicholson et al. (2020) reported that
there were increased connections amongst nodes within the DMN, such as the middle
dorsal pre-frontal cortex, as well as hyperconnectivity within the CEN, in comparison to
individuals with PTSD alone. It was hypothesized that the hyperconnectivity levels within
the DMN and CEN were associated with symptoms of emotional overmodulation and
subsequently the presentation of dissociative symptoms, such as depersonalization and
derealization [15,68,69,78]. Such patterns of connectivity within the DMN and CEN have
been postulated to be associated with changes in cognitive functioning found amongst
individuals with PTSD and co-occurring dissociative symptoms [33]. Among individuals
with PTSD, the findings demonstrated hyperconnectivity between the posterior SN and the
anterior insula relative to individuals with the dissociative subtype [70]. Notably, this pattern of hyperconnectivity between the posterior SN and the anterior insula within the PTSD
group is thought to reflect increased internal and external stimuli processing [56,62,67],
which can contribute to symptoms of hypervigilance and increased reactivity [79].
Disruption to these networks may confer difficulties with top-down cognitive control and bottom-up regulation, subsequently disrupting both cognitive function and
ER [52,55–57]. In many instances, for example, the ability to successfully regulate emotions
is dependent on the ability to inhibit a pre-potent response and executive control [80,81].
For example, cognitive ER, which is the ability to reappraise the meaning of an initial
stimulus such that the emotional response is altered [82–84], is dependent upon cognitive
processes such as working memory, executive functioning, and attention [82,83,85,86]. Notably, impairments in these cognitive functions have been associated with increased risk
of developing psychiatric disorders, such as anxiety [87]. Conversely, ER is necessary for
successful cognitive functioning, such that different ER strategies confer different cognitive
benefits or consequences [80,88]. For example, in a study by Richards and Gross (2000),
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the researchers examined whether differences between the types of ER strategy impacted
memory [88]. Here, it was found that individuals who utilized expressive suppression (i.e.,
inhibiting behavioural urges to act on emotions) performed significantly worse on tasks of
nonverbal and verbal memory versus those who engaged in cognitive reappraisal during
an emotion-inducing slide presentation.
Given the wide-ranging dysfunction associated with the loss of top-down cognitive
control in PTSD, an intervention that assists with reinstating cognitive control and favors the
implementation of generalizable skills to address multiple neurocognitive domains, such as
impulsivity and executive functioning, may be of benefit. Specifically, such an intervention
may not only address the cognitive dysfunction associated with PTSD but also symptoms
associated with PTSD, such as difficulties with ER and dissociation, given the commonalities
amongst the neuroanatomical regions and networks associated with these symptoms [56].
Such an intervention may include goal management training (GMT) [59,89], which is
a skills-based, top-down, cognitive remediation intervention. It is theorized that GMT
targets the brain’s sustained attention system [59,90–92]. This system is activated within
the dorsolateral pre-frontal cortex, posterior parietal cortex, and thalamic regions of the
brain [92], which are regions associated with executive functioning. Moreover, this network
shares similar neuroanatomical regions with the CEN [60,61,64]. Critically, disruption to
the sustained attention system can impede higher-order goal-directed behaviours, such that
automatic responding or other behaviours inconsistent with these goals can subsequently
supersede these goals [59]. This may contribute to difficulties with attention and executive
functioning. The purpose of GMT is to assist with the reinstatement of executive and
supervisory control, such that individuals are taught skills and strategies to monitor
goals [59,93] and to subsequently interrupt automatic responding [59].
GMT has been used to addresses cognitive difficulties across a variety of medical and
neuropsychiatric disorders, including traumatic brain injury (TBI) [59], attention deficit
hyperactivity disorder (ADHD) [94], substance abuse [95], and spina bifida [96]. It consists
of nine two-hour, group-based sessions that provide individuals with psychoeducation,
self-monitoring, and mindfulness-based strategies, as well as other skills to reduce the
frequency and severity of cognitive difficulties, including difficulties with planning, organizing, attention, and memory [89]. A recent meta-analysis found that across various
medical (e.g., TBI, multiple sclerosis) and neuropsychiatric (e.g., ADHD, substance use
disorders) conditions, there was a significant small to moderate positive effect of GMT
on executive functioning (Hedges’ g = 0.227), which remained during follow up testing
(Hedges’ g = 0.549) [97]. Moreover, the meta-analysis revealed significant small to moderate
positive effects of GMT in the domains of working memory (Hedges’ g = 0.438), longterm memory (Hedges’ g = 0.269), instrumental activities of daily living (e.g., cleaning the
house, managing finances, cooking) (Hedges’ g = 0.662), and various psychiatric symptoms
(Hedges’ g = 0.309) [97].
Recent work has sought to apply GMT within psychiatric samples [98,99]. For example,
work by Cameron et al., (2020) examined the feasibility of GMT within an obsessive–
compulsive disorder outpatient sample [98]. Relative to waitlist controls, individuals in
the GMT condition improved on neuropsychiatric measures assessing problem-solving,
planning, impulsivity, attention, and processing speed. Individuals in the GMT condition
also demonstrated significant improvements on subjective ratings of cognitive functioning,
as well as on self-report measures of functioning, including lessened interference of their
obsessive–compulsive disorder symptoms during daily functioning and improvements
in instrumental tasks of daily living. Studies have also begun to directly examine PTSD
and trauma-exposed samples. Specifically, Boyd et al. (2019) conducted an initial openlabel feasibility trial of a modified GMT protocol within an inpatient trauma-exposed
sample [99]. The results from this study demonstrated that patients who participated in a
modified GMT protocol while receiving treatment as usual experienced improvements in
several areas of cognitive functioning, including executive functioning, processing speed,
sustained attention, and verbal memory. In addition, relative to patients who did not
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participate in GMT, patients receiving GMT as an adjunctive treatment also reported an
improvement in their ability to engage in goal-directed behaviours while experiencing
difficulties with ER. Together, these initial findings suggest that GMT may not only be
effective in improving areas of cognitive dysfunction (i.e., both objective and subjective
cognitive functioning) typically associated with PTSD, but also that GMT has the potential
to improve symptoms associated with PTSD, such as difficulties with ER, dissociation, and
difficulties with functioning.
Study Objectives and Hypotheses
To date, no randomized control trial of GMT has been conducted among individuals
experiencing symptoms of PTSD, nor have its effects been fully elucidated within a military,
veteran, and PSP sample expected to experience PTSD and its deleterious impacts at
a higher prevalence than their civilian counterparts [3–5,100]. Moreover, as cognitive
dysfunction can persist among individuals who have received treatment for PTSD [46],
participants who did not meet a current diagnosis of PTSD (e.g., those who had a history of
a PTSD diagnosis or who exhibited symptoms of PTSD that did not meet the full diagnostic
criteria) were also considered for inclusion within the trial. Accordingly, the primary aim
of the present study was to build upon Boyd et al.’s (2019) previous findings [99] and
conduct a pilot randomized controlled trial (RCT) to determine the effectiveness of GMT as
compared to a waitlist (WL) condition in a sample of military personnel, veterans, and PSP
experiencing symptoms of PTSD. We hypothesized that individuals randomly assigned to
receive GMT in comparison to the WL condition would experience improvements in areas
of objective measures of cognitive functioning, including executive functioning, processing
speed, sustained attention, and verbal memory, as well as in a measure of subjective
cognitive functioning. In addition, we hypothesized that participants assigned to the GMT
groups would show significantly greater functional improvement compared to participants
in the WL condition. Finally, we predicted that participants in the GMT condition compared
to those in the WL condition would experience a subsequent improvement in symptoms of
PTSD and symptoms associated with PTSD, including difficulties with ER, dissociation,
depression, and anxiety.
In addition to these objectives and hypotheses, a secondary objective of the study was
to explore the trajectory of symptom change (i.e., self-reported cognitive difficulties, PTSD
symptoms, difficulties with ER, dissociative symptoms, depression symptoms, and anxiety
symptoms) over the course of GMT. It was hypothesized that the severity of these selfreported symptoms would decrease over the course of GMT. Moreover, given the noted
interactions among PTSD symptoms, symptoms associated with PTSD, and cognition,
an additional aim was to explore whether any self-reported symptoms at baseline (e.g.,
self-reported cognitive difficulties, difficulties with ER, etc.) influenced the trajectory of
symptom change across the GMT intervention. Given that these analyses were exploratory
in nature, no hypotheses regarding these outcomes were made.
2. Materials and Methods
This study was approved by the Homewood Health Centre Regional Centre for
Excellence in Ethics (REB 15–29) and is registered at ClinicalTrials.gov (NCT04076839).
A copy of the study protocol is available upon request.
2.1. Participants
The participants were 42 men (64.3% of the sample) and women (35.7% of the sample)
who were either current or former military personnel, veterans, or PSP. Individuals were
recruited by a research coordinator (i.e., a paid staff member of the Homewood Research
Institute (HRI)) during recruitment groups at the Homewood Health Centre (HHC) while
completing treatment on the Program for Traumatic Stress Recovery (PTSR) inpatient unit in
Guelph, Ontario, Canada. Additionally, recruitment occurred at HHC’s Outpatient clinic in
Mississauga, Ontario, the PTSR’s external referral agencies (e.g., Military Family Resource
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Centres, Department of National Security Case Management), external community agencies
and support groups (e.g., Military Causality Support Foundation, Project Trauma Support,
etc.), and social media websites (e.g., Facebook groups, Twitter, etc.) via recruitment posters,
information letters, e-mails, social media postings, and directly through clinician or staff
member referrals at recruitment sites.
To be included in the study, participants had to meet the following inclusion criteria:
(a) be between the ages of 18 and 70; (b) have a diagnosis or a history of a PTSD diagnosis
based upon the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) [101], meet or
exceed the clinical cut-off score on the PTSD Scale for DSM-5 (PCL-5) [102], or have a history
of trauma as indicated on the Life Events Checklist (LEC) [103]; (c) be fluent in written and
spoken English; (d) be able to provide written informed consent; (e) have been discharged
from the PTSR inpatient unit, if applicable. Exclusion criteria included: (a) individuals who
had no history of employment as military personnel, veterans, or PSP; (b) individuals who
had a history of alcohol or substance abuse within the past three months; (c) individuals
who had a history of a medical disorder within the past year known to adversely affect
cognition (e.g., severe TBI).
Participants were randomly allocated to either participate in the GMT group intervention (n = 22) or were assigned to the WL condition (n = 20). Within both conditions, one
individual switched from GMT to the WL condition and from the WL condition to GMT
due to other scheduling commitments, leaving the initial sample sizes the same. Within the
GMT condition, one individual dropped out following their baseline assessment, while
three individuals began the GMT group but dropped out of the group before completing
the sessions. Here, 18 individuals attended and completed the GMT sessions (i.e., 83.3%
of the GMT condition sample attended seven or more GMT sessions). All 18 individuals
completed the GMT post-testing assessments. Fifteen individuals completed the threemonth post-testing assessments. Three individuals did not complete their three-month
post-testing appointments due to loss of contact.
Within the WL condition, two individuals did not meet the criteria for the study during
the baseline assessment and were excluded from the WL sample. Here, one participant
was excluded as they were not a military personnel, veteran, or PSP, while the other
participant identified that they had completed a previous GMT study with the same
principal investigator. Of the 18 eligible individuals, 11 participants completed the postdelay testing. Eleven participants also completed the three-month delay post-testing
assessment; however, one of these participants did not complete the initial post-delay
assessment appointment. Therefore, only ten participants completed both the post-delay
and three-month delay assessment appointments. Nine individuals from the WL condition
attended and completed the GMT sessions (i.e., 88.9% attended seven or more GMT
sessions). See Figure 1 for a CONSORT diagram depicting study recruitment, enrollment,
and loss to follow up. Demographic and clinical characteristics of the initially eligible GMT
and WL participants are reported in Table 1.
Table 1. Demographic and clinical characteristics of eligible participants.
Characteristics

WL
(n = 18)

GMT
(n = 22)

3:15
44.61 (8.54)
15:2:1

10:12
43.95 (6.73)
22:1:0

Demographic characteristics
Sex (female: male)
Age (Mean, (SD))
Race (Caucasian/Aboriginal/Hispanic)
Marital Status
Single
Married or common law
Separated/Divorced
Long-term relationship

% of Sample
5.6
72.2
16.7
5.6

13.6
77.3
0
9.1
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Table 1. Cont.
Characteristics

WL
(n = 18)

GMT
(n = 22)

5.6
5.6
77.8
5.6
5.6

0
9.1
77.3
4.5
9.1

44.4
5.6
22.2
0
22.2
5.6
0

27.3
0
22.7
4.6
27.3
9.1
9.1

0
5.6
94.4
0

18.2
13.6
95.5
27.3

36.00 (14.33)
77.8

40.86 (12.67)
90

Highest Level of Education Completed
Completed high school
Some college or university
Completed college or university
Some graduate level education
Completed graduate degree
Current Employment Status
Working full time
Working part time
Medical Leave/Long-term Disability
Modified duties/Return to work
On leave/WSIB
Not currently employed
Other
Military, Veteran, or Public Safety Personnel Status
Military
Veteran
Public Safety Personnel
Both
Clinical characteristics
CAPS-5—Severity Score (Mean, (SD))
CAPS-5—PTSD Criteria Met (% of Sample)
Additional M.I.N.I. 7.0.2 diagnoses
Major Depressive Disorder
Generalized Anxiety Disorder
Social Anxiety Disorder
Panic Disorder
Agoraphobia
Alcohol Use Disorder, Past 12 Months
Substance Use Disorder, Past 12 Months
Binge Eating Disorder
IQ
WTAR Estimated IQ
WASI-II FSIQ

% of Sample
61.1
27.8
27.8
16.7
11.1
5.6
0
15.0

63.6
54.5
50.0
27.3
40.9
13.64
4.55
4.55
Mean (SD)

113.44 (6.08)
105.56 (16.00)

113.32 (5.38)
108.45 (14.13)

Note. WL = Waitlist; GMT = Goal Management Training; WSIB = Workplace Safety and Insurance Board;
CAPS-5 = Clinician-Administered PTSD Scale for DSM-5; IQ = Intelligence Quotient; WTAR = Wechsler Test
of Adult Reading; WASI-II = Wechsler Abbreviated Scale of Intelligence, Second Edition; M.I.N.I. 7.0.2 = Mini
International Neuropsychiatric Interview 7.0.2.

2.2. Experimental Design and Procedure
This study followed a pilot RCT with a parallel experimental design, which recruited
and followed participants between October 2017 and August 2019. The website https://www.
sealedenvelope.com/simple-randomiser/v1/lists (last accessed on 5 September 2017) was used
to generate the random allocation sequence. Ten blocks were specified so that there would be an
equal number of participants allocated to the GMT and WL conditions [104,105]. A randomization list was created for each site where participants were assessed and participated in GMT (i.e.,
HRI, Guelph, Ontario and HHC Outpatient Clinic, Mississauga, Ontario). The randomization
lists were password protected and were only accessible by the research coordinator.
The research coordinator contacted participants who indicated their interest in the
study and screened them for their eligibility. If eligible, the initial baseline testing appointment was scheduled with a trained assessor (i.e., a graduate student or individual with
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Those who participated in GMT were administered the same battery and schedule of
self-report measures during the GMT intervention (i.e., initial GMT session and every third
session thereafter).
2.3. Study Conditions
GMT. As previously described, GMT consists of nine two-hour, weekly, group-based sessions that provide individuals with psychoeducation, self-monitoring strategies, mindfulnessbased strategies, and other skills to reduce the frequency and severity of cognitive difficulties,
including difficulties with planning, organizing, attention, and memory [89]. The GMT sessions were facilitated by an occupational therapist with significant GMT facilitation experience
and treatment of military personnel, veterans, and PSPs with PTSD and trauma histories.
Given this, GMT was tailored to this population by including psychoeducation and examples
related to how PTSD and trauma can affect cognition (e.g., acknowledging how difficulties
with dissociation, ER, and hypervigilance can affect attentional resources). These modifications to the protocol were not previously assessed and were also being piloted within this
study. GMT also was co-facilitated by a clinical psychology graduate student who assisted
with the group’s administration and session content, as needed.
WL. Participants who were randomly assigned to the WL condition were required to
wait for at least a three-month period after which they were offered the ability to participate
in GMT. Participants completed testing following the initial nine-week waiting period, as
well at the three-month follow-up. As previously described, following their participation
in GMT (if elected), participants were assessed following the intervention and again at
3-months post-intervention.
2.4. Measures
2.4.1. Clinician-Administered Interviews
The Mini International Neuropsychiatric Interview 7.0 (M.I.N.I.) [106] is a semi-structured,
clinician-administered interview, which assesses 17 psychiatric disorders, including mood,
anxiety, alcohol, and substance use disorders according to the DSM-5 [1]. The M.I.N.I. was
only administered during baseline testing.
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) [101] is a semi-structured
interview that assesses the DSM-5’s PTSD diagnostic criteria in the past month. It assesses
the onset, duration, frequency, and intensity of symptoms. The CAPS-5 was administered
at baseline only.
2.4.2. Neuropsychological Assessment
A standardized neuropsychological assessment battery aimed at assessing intellectual functioning, executive functioning, processing speed, attention, and memory was
administered to both GMT and WL condition participants.
Intellectual functioning (assessed at baseline only): (a) the Wechsler Test of Adult Reading
(WTAR) [107] was used to assess pre-morbid intellectual functioning in adults; (b) the
Wechsler Abbreviated Scale of Intelligence—Second Addition (WASI-II) [108] is a brief estimate
of intelligence. Here, the Vocabulary and Matrix Reasoning subtests were administered to
yield a Full-Scale Intelligence Quotient (FSIQ).
Measures of executive functioning, processing speed, and attention (administered at
baseline, post-intervention, and at three months post-intervention for the GMT and WL
conditions): (a) the Controlled Oral Word Association Task (COWAT) [109] was used to assess
verbal fluency, including phonemic (FAS) and semantic (animals) fluency; (b) the Stroop
Color and Word Test [110,111] was used to assess processing speed (word and color reading)
and sensitivity to suppress habitual responses; (c) the Delis-Kaplan Executive Function System
(DKEFS) Tower Test [112] was used as a measure of planning, rule learning, response
inhibition, and perseveration; (d) the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Digit
Symbol Coding Subtest [113] assessed processing speed in adults; (e) the Trail Making Test
(TMT) Part A and B [109] was used as a measure of attention, speed, and mental flexibility.
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Participants were required to connect numbers in sequential order (TMT part A) and
numbers and letters in alternating order (TMT part B) as quickly as possible; (f) Conners’
Continuous Performance Task (CPT 3.0) [114] was used as a measure of inattentiveness,
impulsivity, sustained attention, and vigilance.
Declarative memory (administered at baseline, post-intervention, and at three months
post-intervention for the GMT and WL conditions): The California Verbal Learning Test II
(CVLT-II) [115] is a multiple-trial, word list learning task, which provides indices of immediate and delayed memory performance, interference learning, and recognition.
2.4.3. Subjective Cognition
The Cognitive Failures Questionnaire (CFQ) [116,117] is a 25-item self-report measure
that captures daily errors in distractibility, blunders, names, and memory. The CFQ has
been demonstrated to have good construct validity and internal consistency (α = 0.76–0.86)
for its four subscales [117]. The CFQ was assessed at all clinician-administered assessment
time points (i.e., baseline, post-intervention, and at three months post-intervention for the
GMT and WL conditions) and during the GMT intervention (i.e., initial, third, sixth, and
final GMT sessions) for those who initially were allocated to the GMT condition or who
elected to participate in GMT following their participation in the WL condition.
2.4.4. Functional Outcomes
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) [118]
was administered to assess individuals’ functioning across six domains, including cognition, mobility, self-care, getting along with others, life activities, and participation in
the community. It has demonstrated high internal consistency across its six domains
(α = 0.94–0.96), good test–retest reliability, and good convergence with other comparable measures [118]. It was administered during all clinician-administered assessment
time points.
2.4.5. Self-Report Symptom Measures
The PTSD Checklist for DSM-5 (PCL-5) [102] was administered to participants to assess the severity of PTSD symptoms according to the diagnostic criteria outlined in the
DSM-5 [1]. The symptom domains included intrusive symptoms, avoidance, negative alterations in mood and cognitions, and alterations in arousal and reactivity [1,102]. Participants
rated the severity of their symptoms in the past month on a Likert scale from 0 (not at all) to
4 (extremely). A cut-point of 33 is suggested to indicate a probable PTSD diagnosis [119]. It
has demonstrated high internal consistency among military (α = 0.95) [119] and veteran
(α = 0.95) [120] samples. This measure was administered at all clinician-administered
assessment time points and during the GMT intervention.
The Difficulties in Emotion Regulation Scale (DERS) [10] is a 36-item self-report measure,
which assesses difficulties with ER across six domains, including difficulties with accepting
negative emotions; difficulties completing tasks or goals due to negative emotions; difficulties with controlling impulses while experiencing distressing emotions; difficulties
with awareness of emotional experiences; negative beliefs regarding the ability to regulate emotions; and difficulties with insights regarding emotions. Higher scores indicated
greater dysfunction with ER. The DERS was shown to have good psychometric properties,
including internal consistency (α = 0.93) and construct validity [10]. This measure was
administered at all clinician-administered assessment time points for the GMT and WL
conditions. It also was administered during the GMT intervention.
The Multiscale Dissociation Inventory (MDI) [121] is a 30-item self-report measure, which
assesses six domains of dissociative symptoms over the past month, including disengagement, depersonalization, derealization, emotional constriction, memory disturbance, and
identity dissociation. The MDI Total score has been demonstrated to have high internal consistency (α = 0.96) [121]. This measure also was administered at all clinician-administered
assessment time points and during the GMT intervention.

Brain Sci. 2022, 12, 377

12 of 32

The Beck Depression Inventory-II (BDI-II) [122] is a 21-item self-report questionnaire
that assesses the presence and severity of symptoms of depression over the past 30 days.
Symptoms assessed include hopelessness and irritability, feelings of guilt or feelings of
being punished, as well as physical symptoms such as fatigue, weight loss, and loss of
interest in sex. Respondents rate their symptoms on a Likert scale from 0 to 3, with higher
scores reflecting greater symptom severity. The BDI-II has been demonstrated to have high
internal consistency in psychiatric outpatients (α = 0.91) [123] and adequate convergent
and discriminant validity [122]. The BDI-II was administered at all clinician-administered
testing sessions and during the GMT intervention.
The Beck Anxiety Inventory (BAI) [124] is a 21-item self-report questionnaire that assesses anxiety symptoms over the past 30 days. The items consist of common symptoms
of anxiety, such as numbness, tingling, sweating, and fear of perceived catastrophic outcomes. Participants rate their symptoms on a four-point Likert Scale from 0 (not at all) to
3 (severely). It has been demonstrated to have excellent reliability in psychiatric outpatient
samples (α = 0.92) [125]. It was administered at all clinician-administered testing sessions
and during the GMT intervention.
2.5. Statistical Methods
Data were analyzed using IBM SPSS Version 26.0. Independent samples t-tests and chisquare tests were used to analyze differences in demographic, clinical, neuropsychological,
and self-report variables between WL and GMT groups at baseline.
To assess our primary objectives, a series of 2 (time) × 2 (group) ANOVAs were
conducted to assess the differences between the WL and GMT conditions from pre- to postintervention, with analyses completed on participants who did not have any missing data
from pre- to post-intervention for each measure of interest (i.e., modified intention-to-treat
analysis). Subsequently, sample sizes are indicated for each measure and its analysis. Effect
sizes were reported as partial eta-squared (interpreted as small = 0.01, medium = 0.10, and
large = 0.25) for the neuropsychological, subjective cognition, functional, and self-report
symptom measures. Given the large number of neuropsychological and self-report variables available from this comprehensive battery relative to the small number of participants
in the pilot sample, the clinician-administered 3-month assessment time point was excluded
from the primary analyses to minimize the risk of type I error. Moreover, due to the pilot
nature of this study, the results of the ANOVAs were followed up with simple main effects
analyses based on significant main effects (e.g., time or condition), observations of effect
sizes, or inspection of means and SDs between the groups, as the pilot sample may not
have been large enough in every case to assess results based on p-values alone.
To evaluate our secondary objectives in examining the trajectory of self-reported
symptom changes and the effects of baseline variables on the trajectory of symptom changes
during the GMT intervention, a series of one- and two-level hierarchical linear models
was conducted. Hierarchical linear modelling (HLM) [126] was used given its ability to
evaluate individual differences in the trajectory of change over time, and because it can
accommodate missing data at level 1. The restricted maximum likelihood approach was
used as the method for parameter estimation. The primary outcome variables were the
CFQ, PCL-5, DERS, MDI, BDI-II, and BAI total scores, with the assessment time point as
a level 1 predictor. Baseline PCL-5, DERS, MDI, BDI-II, and BAI total scores were used
as predictors at level 2 in subsequent analyses, and level 2 variables were centred around
the grand mean. All analyses assessed changes from baseline to post-intervention across
six time points with the unit of time standardized to one week. Specifically, these analyses
included all participants who participated in the GMT intervention (i.e., participants who
were allocated to the GMT condition and those WL participants who agreed to participate
in GMT following their wait period) and included their self-report assessments before,
during, and after the GMT intervention. The one-level models assessed the trajectory
of change in a single variable over time, whereas each of the two-level models assessed
the effect of a level 2 predictor on the trajectory of change in the self-report symptom
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measures over time. Individuals missing greater than 30% of the data were excluded from
the analysis. Analyses were completed using the HLM 7.0 statistical program.
3. Results
The participants’ mean age across the WL and GMT conditions was 44.25 (SD = 7.50).
Further, the mean years of education for the sample was 17.27 (SD = 2.87). Within the WL
and GMT conditions, 77.8% and 90% of the participants, respectively, met the diagnostic
criteria for PTSD according to the CAPS-5. Overall, 85.0% of the participants met the criteria
for a diagnosis of PTSD across both samples.
With respect to the pre-morbid IQ (i.e., WTAR Estimated IQ), participants in the WL
and GMT conditions had mean IQ scores of 113.44 (SD = 6.08) and 113.32 (SD = 5.38),
respectively. Further, the mean estimated IQs (i.e., WASI-II FSIQ) within the WL and GMT
conditions were 105.56 (SD = 16.00) and 108.45 (SD = 14.13), respectively. Collectively,
these pre-morbid and estimated IQ scores represent scores between the average and high
average range.
No significant differences emerged for the demographic and clinical characteristics between the WL and GMT conditions at baseline. All variables were assessed for homogeneity
of variance (Levene’s test) and normality (using Kolmogorov–Smirnov and Shapiro-Wilk
tests) prior to analyses being conducted. There were several violations of homogeneity of
variance and normality (i.e., p < 0.05). Transformation of variables were completed [127];
however, the normality and homogeneity of variance were not improved. Therefore, the
results of the non-transformed variables are reported. Subsequently, cautious interpretation
of the findings is warranted.
Importantly, no adverse effects were reported as a result of participating in GMT.
3.1. Pre- and Post-Analysis of Neuropsychological Assessment Performance
Means and SDs for the pre-treatment neuropsychological assessment performance in
each of the WL and GMT groups are presented in Table 2. A series of t-tests were performed
on these data to ensure no baseline differences in cognitive performance between groups.
All results were insignificant (p = 0.099 to 0.996).
Table 2. Means and SDs for baseline neuropsychological assessment performance between WL
and GMT.
Variable

Group

n

Mean

SD

WL
GMT
WL
GMT

18
22
18
22

42.28
41.41
48.28
49.32

8.98
10.25
12.84
12.81

WL
GMT
WL
GMT
WL
GMT
WL
GMT

18
22
18
22
18
22
18
22

36.78
37.55
39.17
41.14
43.44
44.09
49.56
49.41

10.64
11.28
10.43
10.74
8.00
11.17
6.78
6.96

WL
GMT
WL
GMT

18
22
18
22

11.22
11.45
10.61
9.23

2.53
2.18
2.57
2.58

COWAT
FAS T Score
Animals T Score
Stroop Color and Word Test
Word T-Score
Color T-Score
Color-Word Trial T Score
Interference T-Score
DKEFS Tower Test
Total Scaled Score
First Move Time Scaled Score
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Table 2. Cont.
Variable

Group

n

Mean

SD

Time Per Move Scaled Score

WL
GMT
WL
GMT
WL
GMT

18
22
18
22
18
22

9.61
8.82
9.17
9.50
0.78
0.45

2.85
3.51
2.68
3.40
1.16
0.67

WL
GMT

18
22

9.78
9.36

3.00
2.26

WL
GMT
WL
GMT

17
21
16
21

50.00
47.43
46.88
44.67

9.25
11.47
9.16
10.73

WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT

18
22
18
22
18
22
18
22
18
22
18
22

47.94
47.95
51.89
52.27
48.94
50.27
46.83
43.68
50.50
52.00
45.94
48.55

8.35
5.10
7.75
8.95
6.03
8.40
8.58
7.93
11.13
7.80
3.12
7.58

WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL
GMT

18
22
18
22
18
22
18
22
18
22
18
22
18
22
18
22
18
22
18
22
18
22

−0.22
0.52
−0.14
−0.21
50.61
55.68
0.14
0.02
0.17
−0.14
0.17
0.09
0.11
−0.07
−0.08
−0.09
0.14
0.07
0.23
−0.16
−0.06
0.25

1.73
1.15
0.78
0.97
10.88
10.37
1.61
0.88
0.73
1.20
0.82
1.07
0.96
1.15
0.77
0.93
1.30
1.13
1.53
1.00
1.14
1.09

Move Accuracy Scaled Score
Rule Violations
WAIS-IV
Digit Symbol Coding Scaled Score
TMT
TMT Part A T-Score
TMT Part B T-Score
CPT 3.0 a
Omissions T Score
Commissions T Score
Detectability T Score
Hit Reaction Time T Score
Variability T Score
Perseverations T Score
CVLT-II
Trial 1 Z Score
Trials 5 Z Score
Trial 1-15 Z Score
Trial B Z Score
Short-Delay Free Recall Z Score
Short-Delay Cued Recall Z Score
Long-Delay Free Recall Z Score
Long-Delay Cued Recall Z Score
Repetitions Z Score
Intrusions Z Score
Discriminability Z Score

Note. WL = Waitlist; GMT = Goal Management Training; COWAT = Controlled Oral Word Association Task; FAS
represents the letters “F”, “A”, and “S” for the COWAT subtest; DKEFS = Delis-Kaplan Executive Function System;
WAIS-IV = Wechsler Adult Intelligence Scale Fourth Edition; TMT = Trail Making Test; CPT 3.0 = Conner’s Continuous Performance Test—Third Edition; CVLT-II = California Verbal Learning Test—Second Edition. a Higher T
scores for CPT 3.0 indicates poorer performance.
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The results of the 2 × 2 ANOVAs for the neuropsychological assessments are reported
in Table 3.
Table 3. 2 × 2 ANOVA table for neuropsychological assessments.
Tests of Executive Functioning, Processing Speed, and Attention
Neuropsychological Test

Neuropsychological Subtest

Source

F

p

η2 p

FAS T Score

Time
Condition
Time * Condition
Time
Condition
Time * Condition

9.044
0.373
0.149
0.932
0.664
0.022

0.006 **
0.547
0.703
0.343
0.422
0.883

0.251
0.014
0.005
0.033
0.024
0.001

Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition

3.352
0.002
0.056
5.137
0.101
1.564
12.477
0.016
2.903
9.402
0.076
0.953

0.078
0.968
0.815
0.032 *
0.754
0.222
0.002 **
0.901
0.100
0.005 **
0.785
0.338

0.110
0.000
0.002
0.160
0.004
0.055
0.316
0.001
0.097
0.258
0.003
0.034

Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition

3.557
0.251
0.002
11.186
6.559
1.945
16.065
1.550
4.066
0.035
0.812
0.730
5.935
1.335
3.393

0.071
0.621
0.964
0.003 **
0.017 *
0.175
0.000 **
0.224
0.054
0.854
0.376
0.401
0.022 *
0.258
0.077

0.120
0.010
0.000
0.301
0.201
0.070
0.382
0.056
0.135
0.001
0.030
0.027
0.186
0.049
0.115

Time
Condition
Time * Condition

12.675
1.054
0.400

0.001 **
0.314
0.533

0.319
0.038
0.015

Time
Condition
Time * Condition
Time
Condition
Time * Condition

0.604
0.223
0.198
7.581
0.025
0.056

0.445
0.641
0.660
0.011 *
0.875
0.815

0.024
0.009
0.008
0.233
0.001
0.002

Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition

0.018
0.005
2.133
17.009
0.012
0.148
4.912
0.328
1.147

0.895
0.946
0.156
0.000 **
0.915
0.703
0.036*
0.572
0.294

0.001
0.000
0.076
0.395
0.000
0.006
0.159
0.012
0.042

COWAT a
Animals T Score

Word T Score
Stroop Color and Word Test a

Color T Score

Color-Word T Score

Interference T Score

DKEFS Tower Test b

Total Score Scaled Score

First Move Time Scaled Score

Time Per Move Scaled Score

Move Accuracy Scaled Score

Rule Violations

WAIS-IV a

Digit Symbol Coding Scaled Score
TMT Part A T Score

TMT c
TMT Part B T Score

CPT 3.0 b

Omissions T Score

Commissions T Score

Detectability T Score
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Table 3. Cont.
Tests of Executive Functioning, Processing Speed, and Attention
Neuropsychological Test

Neuropsychological Subtest

Source

F

p

η2 p

Hit Reaction Time T Score

Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition

0.235
0.107
2.078
0.450
1.086
0.375
6.259
0.916
0.263

0.632
0.746
0.161
0.508
0.307
0.546
0.019 *
0.347
0.613

0.009
0.004
0.074
0.017
0.040
0.014
0.194
0.034
0.010

0.032
2.997
0.228
14.603
0.293
0.690
0.592
1.668
1.247
0.944
0.494
2.976
0.129
0.356
7.963
0.217
0.880
3.530
0.475
0.426
1.955
0.824
1.621
2.372
0.107
0.884
0.604
2.495
0.480
0.782
1.838
1.161
0.472

0.860
0.095
0.637
0.001 **
0.593
0.413
0.448
0.207
0.274
0.340
0.488
0.096
0.722
0.556
0.009 **
0.645
0.357
0.071
0.496
0.519
0.173
0.372
0.214
0.135
0.746
0.355
0.444
0.126
0.494
0.384
0.186
0.291
0.498

0.001
0.100
0.008
0.351
0.011
0.025
0.021
0.058
0.044
0.034
0.018
0.099
0.005
0.013
0.228
0.008
0.032
0.116
0.017
0.016
0.068
0.030
0.057
0.081
0.004
0.032
0.022
0.085
0.017
0.028
0.064
0.041
0.017

Variability T Score

Perseverations T Score

Tests of Declarative Memory
Trial 1 Z Score
CVLT-II a
Trial 5 Z Score

Trial 1-5 T Score

Trial B Z Score

Short Delay Free Recall Z Score

Short Delay Cued Recall Z Score

Long Delay Free Recall Z Score

Long Delay Cued Recall Z Score

Repetitions Z Score

Intrusions Z Score

Discriminability Z Score

Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition

Note. GMT = Goal Management Training; WL = Waitlist; COWAT = Controlled Oral Word Association Task; FAS
represents the letters “F”, “A”, and “S” for the COWAT subtest; DKEFS = Delis-Kaplan Executive Function System;
WAIS-IV = Wechsler Adult Intelligence Scale Fourth Edition; TMT = Trail Making Test; CPT 3.0 = Conner’s
Continuous Performance Test – Third Edition; CVLT-II = California Verbal Learning Test – Second Edition. a GMT
n = 18, WL n = 11. b GMT n = 18, WL n = 10. c GMT n = 17, WL n = 10. Note: * p < 0.05. ** p < 0.01.

3.1.1. Tests of Executive Functioning, Processing Speed, and Attention
COWAT. There was a main effect of time for the FAS subtest (F(1, 27) = 9.044, p = 0.006,
η2 p = 0.251), indicating improved task performance for both the GMT and WL conditions from
pre- to post-intervention. Simple main effects analyses revealed that while participants’ scores
in the GMT condition improved significantly (F(1, 27) = 7.587, p = 0.010, η2 p = 0.219) from
pre- to post-intervention, participants’ scores in the WL condition did not (F(1, 27) = 2.768,
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p = 0.108, η2 p = 0.093). This suggests that GMT had a medium effect on verbal fluency. There
were no significant interactions or main effects for the COWAT Animals subtest (ps = 0.343
to 0.883).
Stroop Color and Word Test. The results of the 2 × 2 ANOVA for the Stroop Color and
Word Test demonstrated significant main effects of time in the color subtest (F(1, 27) = 5.137,
p = 0.032, η 2 p = 0.160), the color–word subtest (F(1, 27) = 12.477, p = 0.002, η 2 p = 0.316), and
the interference score (F(1, 27) = 9.402, p = 0.005, η 2 p = 0.258), suggesting improvements for
both groups from pre- to post-intervention. Simple main effects analyses were carried out.
Notably, the results demonstrated that across the color (F(1, 27) = 4.982, p = 0.034, η 2 p = 0.156),
color–word (F(1, 27) = 11.043, p = 0.003, η 2 p = 0.290), and interference (F(1, 27) = 6.582, p = 0.016,
η 2 p = 0.196) scores, individuals’ scores within the WL condition improved significantly, while
those in the GMT condition (ps = 0.417, 0.149, and 0.101, respectively) did not.
DKEFS Tower Test. There was a significant main effect of time (F(1, 26) = 11.186,
p = 0.003, η 2 p = 0.301) and condition (F(1, 26) = 6.559, p = 0.017, η 2 p = 0.201) for the DKEFS
first move time scaled score from pre- to post-intervention. Simple main effects analyses
revealed that there was a significant increase in task initiation time from pre- to postintervention for those participants in GMT (F(1, 26) = 15.722, p = 0.001, η 2 p = 0.377), but
not for those in the WL condition (F(1, 26) = 1.479, p = 0.235, η 2 p = 0.054). This suggests
that following GMT, individuals took longer to make their first move on the task than
those in the WL condition. These findings represent a large effect. Moreover, there were
also significant main effects of time for the time per move scaled score (F(1, 26) = 16.065,
p < 0.001, η 2 p = 0.382) and rule violations (F(1, 26) = 5.935, p = 0.022, η 2 p = 0.186). Simple
main effects analyses for the time per move scaled score demonstrated that there was a
significant increase in the amount of time taken per move from pre-to post-intervention
for those participants in GMT (F(1, 26) = 25.405, p < 0.001, η 2 p = 0.494), but not for those
participants in the WL condition (F(1, 26) = 1.543, p = 0.225, η 2 p = 0.056). Moreover, the
simple main effects for rule violations demonstrated that there was a significant decrease
(i.e., less rule breaking) for the participants in the WL condition over time (F(1, 26) = 7.118,
p = 0.013, η 2 p = 0.215), but not for GMT participants (F(1, 26) = 0.247, p = 0.623, η 2 p = 0.009).
WAIS-IV Digit Symbol Coding Subtest. Analyses demonstrated that there was a significant main effect for time (F(1, 27) = 12.675, p = 0.001, η 2 p = 0.319), with simple main effects
revealing significant increases in participants’ scores for both the GMT (F(1, 27) = 5.650,
p = 0.025, η 2 p = 0.173) and WL (F(1, 27) = 7.079, p = 0.013, η 2 p = 0.208) conditions from preto post-intervention.
TMT. There was a significant main effect of time (F(1, 25) = 7.581, p = 0.011, η 2 p = 0.233)
for the TMT part B score from pre- to post-intervention. Notably, there was a simple
main effect demonstrating a significant increase in scores for the participants in the GMT
condition (F(1, 25) = 4.277, p = 0.049, η 2 p = 0.146), suggesting a reduction in the time taken
to complete the task. Moreover, those in the WL condition also demonstrated an increase
in their TMT part B scores over time; however, this result did not reach the alpha level of
significance (F(1, 25) = 3.549, p = 0.071, η 2 p = 0.124).
CPT 3.0. There were significant improvements (i.e., decreases) in commissions
(F(1, 26) = 17.009, p < 0.001, η 2 p = 0.395) and detectability (F(1, 26) = 4.912, p = 0.036,
η 2 p = 0.159) scores across time for both groups. Furthermore, there was a significant
increase in perseverations across time for both groups (F(1, 26) = 6.259, p = 0.019,
η 2 p = 0.194). With respect to commissions, simple main effects demonstrated significant decreases for both the GMT (F(1, 26) = 14.233, p = 0.001, η 2 p = 0.354) and WL
(F(1, 26) = 5.437, p = 0.028, η 2 p = 0.173) conditions from pre- to post-intervention. Moreover, simple main effects analyses demonstrated a similar significant decrease for
detectability from pre- to post-intervention within the GMT condition (F(1, 26) = 7.564,
p = 0.011, η 2 p = 0.225), but not within the WL condition (F(1, 26) = 0.510, p = 0.481,
η 2 p = 0.019). These findings represented a medium to large effect size. Finally, analyses
of the simple main effect for perseverations demonstrated a significant increase in scores
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(i.e., a worsening) within the GMT condition (F(1, 26) = 6.360, p = 0.018, η 2 p = 0.197),
but not the WL condition (F(1, 26) = 1.539, p = 0.226, η 2 p = 0.056).
3.1.2. Declarative Memory
CVLT. Results of the 2 × 2 ANOVAs for the CVLT also reveal several significant
effects. Critically, there was a significant group x time interaction for the CVLT-II Short
Delay Free Recall Z score (F(1, 27) = 7.963, p = 0.009, η 2 p = 0.228), with simple main effects
indicating that participants in the GMT condition freely recalled a greater number of words
from a list (F(1, 27) = 3.997, p = 0.056, η 2 p = 0.129). This finding, however, did not reach
the alpha threshold for significance. Those in the WL condition experienced a decline in
their ability to freely recall words from a list; however, this finding also did not reach the
alpha threshold for significance (F(1, 27) = 4.076, p = 0.054, η 2 p = 0.131). Further, there
was a significant main effect of time for the Trial 5 Z scores (F(1, 27) = 14.603, p = 0.001,
η 2 p = 0.351). Here, simple main effects revealed a significant improvement for participants
in the GMT condition (F(1, 27) = 14.264, p = 0.001, η 2 p = 0.346), with those participants in
the WL condition also improving (F(1, 27) = 3.602, p = 0.068, η 2 p = 0.118), but did not reach
the alpha level for significance.
3.2. Pre and Post-Analysis of Subjective Cognition, Functioning, and Self-Report Symptom Measures
A series of t-tests were conducted to assess baseline differences between the GMT and
WL conditions on each of the self-report variables. No significant differences were present
between the two groups (ps = 0.057 to 0.292). The means and SDs for those participants
who completed both pre- and post-intervention assessments on each self-report measure
are reported in Table 4.
Table 4. Means and SDs for pre- and post-intervention scores for the subjective cognition, functioning,
and self-report symptom measures for WL and GMT groups.
Measures

Group (n) a

CFQ

WL (11)
GMT (18)
WL (11)
GMT (17)
WL (11)
GMT (14)
WL (11)
GMT (17)
WL (11)
GMT (18)
WL (10)
GMT (18)
WL (9)
GMT (18)

WHODAS Score
PCL-5 Total Score
DERS Total Score
MDI Total Score
BDI-II Total Score
BAI Total Score

Pre-Intervention

Post-Intervention

Mean

SD

Mean

SD

50.82
54.50
31.44
42.03
38.55
38.71
94.09
101.53
50.36
55.61
25.30
28.11
26.33
25.44

12.55
20.54
11.35
19.67
15.92
12.08
23.79
23.87
15.48
16.68
8.31
12.10
14.20
12.55

49.09
46.50
32.39
33.70
39.82
32.71
90.91
90.53
52.82
49.56
21.40
21.11
23.56
18.50

12.79
15.74
14.51
13.79
15.77
14.90
24.00
23.55
16.67
12.52
6.62
11.21
12.08
10.15

Note. WL = Waitlist; GMT = Goal Management Training; CFQ = Cognitive Failures Questionnaire; WHODAS = World
Health Organization Disability Assessment Schedule 2.0; PCL-5 = PTSD Checklist for DSM-5; DERS = Difficulties
in Emotion Regulation Scale; MDI = Multiscale Dissociation Inventory; BDI-II = Beck Depression Inventory II;
BAI = Beck Anxiety Inventory. a Sample sizes reflect the total number of participants who did not have any missing
data for the indicated measure at pre- and post-intervention.

The results of the 2 × 2 ANOVAs for the subjective cognition, functional, and selfreport symptom measures are reported in Table 5. Inspection of the means for the CFQ
total score indicated a potential effect of the GMT intervention (i.e., an approximate
eight-point decrease versus a two-point decrease in mean CFQ total scores between GMT
and the WL condition; Table 4). Indeed, simple main effect analyses demonstrated that
the CFQ total score for those participants in the GMT condition decreased significantly
over time (F(1, 27) = 5.344, p = 0.029, η 2 p = 0.165), while it did not for those in the WL

Brain Sci. 2022, 12, 377

19 of 32

condition (F(1, 27) = 0.152, p = 0.699, η 2 p = 0.006), suggesting a medium effect of the GMT
intervention on subjective cognitive function.
Table 5. The 2 × 2 ANOVA tables for the subjective cognition, functioning, and self-report
symptom measures.
Measures

Source

F

p

η2 p

CFQ Total Score

Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition
Time
Condition
Time * Condition

2.997
0.009
1.246
3.516
1.092
5.552
1.538
0.388
3.641
4.473
0.167
1.359
0.567
0.035
3.164
9.797
0.115
0.792
5.088
0.456
0.935

0.095
0.924
0.274
0.072
0.306
0.026
0.227
0.539
0.069
0.044
0.686
0.254
0.458
0.854
0.087
0.004
0.737
0.382
0.033
0.506
0.343

0.100
0.000
0.044
0.119
0.040
0.176
0.063
0.017
0.137
0.147
0.006
0.050
0.021
0.001
0.105
0.274
0.004
0.030
0.169
0.018
0.036

WHODAS Score
PCL-5 Total Score

DERS Total Score
MDI Total Score

BDI-II Total Score
BAI Total Score

Note. CFQ = Cognitive Failures Questionnaire; WHODAS = World Health Organization Disability Assessment
Schedule 2.0; PCL-5 = PTSD Checklist for DSM-5; DERS = Difficulties in Emotion Regulation Scale; MDI = Multiscale
Dissociation Inventory; BDI-II = Beck Depression Inventory II; BAI = Beck Anxiety Inventory.

Moreover, the WHODAS score showed a significant group x time interaction, with
simple main effects indicating that scores for the GMT condition significantly decreased over
time (F(1, 26) = 11.39, p = 0.002, η 2 p = 0.305), while the WL group did not (F(1, 26) = 0.095,
p = 0.760, η 2 p = 0.004). These results indicate a large positive effect of GMT on functioning.
The interaction for the PCL-5 total score approached significance (F(1, 23) = 3.641,
p = 0.069, η 2 p = 0.137). Simple main effects showed that the PCL-5 total score for participants in the GMT condition decreased significantly over time (F(1, 23) = 5.63, p = 0.026,
η 2 p = 0.197), while it did not for those in the WL condition (F(1, 23) = 0.199, p = 0.660,
η 2 p = 0.009). This suggests a reduction in PTSD symptom severity following participation
in the GMT intervention.
There also was a significant main effect of time for the DERS total score (F(1, 26) = 4.473,
p = 0.044, η 2 p = 0.147; Table 5), suggesting that both groups experienced decreases in their
DERS total scores from pre- to post-intervention. The results of the simple main effects
revealed that participants in the GMT condition showed a significant reduction in DERS
total score (F(1, 26) = 6.85, p = 0.015, η 2 p = 0.209); however, this finding was not observed for
those participants in the WL condition (F(1, 26) = 0.371, p = 0.548, η 2 p = 0.014). These results
indicate a medium effect of the GMT intervention on reductions in difficulties with ER.
With respect to MDI total score, the interaction between time and intervention approached significance (F(1, 27) = 3.164, p = 0.087, η 2 p = 0.105). Here, simple main effects
demonstrated that following their participation in the GMT condition, participants experienced significant reductions in MDI total scores (F(1, 27) = 4.223, p = 0.050, η 2 p = 0.135),
whereas those participants in the WL condition did not (F(1, 27) = 0.424, p = 0.520,
η 2 p = 0.015). This represented a moderate effect of GMT on dissociative symptoms.
Finally, there also were significant main effects of time for BDI-II (F(1, 26) = 9.797,
p = 0.004, η 2 p = 0.274) and BAI (F(1, 25) = 5.088, p = 0.033, η 2 p = 0.169) total scores across
both conditions. Specifically, for the BDI-II total score, simple main effects revealed that

Brain Sci. 2022, 12, 377

20 of 32

those participants in the GMT condition showed a significant reduction in total score from
pre- to post-intervention (F(1, 26) = 11.314, p = 0.002, η 2 p = 0.303), which was not found for
those participants in the WL condition (F(1, 26) = 1.951, p = 0.174, η 2 p = 0.070).
A similar result was observed for the BAI with reductions in BAI total scores for those
participants in the GMT condition (F(1, 25) = 7.788, p = 0.010, η 2 p = 0.238), but not for those
participants in the WL condition (F(1, 25) = 0.623, p = 0.437, η 2 p = 0.024). These results
indicate medium to large effects for self-reported depressive and anxiety symptoms for
those participants in the GMT condition.
3.3. Trajectory of Change for Subjective Cognition and Self-Report Symptom Measures
Table 6 demonstrates the level 1 HLM analyses for the trajectory of subjective cognition and symptom severity changes over time for those individuals who participated
in GMT (i.e., either initially randomized to GMT or those individuals from the WL who
participated after their waiting period). With respect to subjective cognition, CFQ total
scores significantly decreased across time (b = −1.44, t(33) = −2.72, p = 0.010). Furthermore,
the PCL-5 total score (b = −2.23, t(33) = −5.97, p < 0.001), DERS total score (b = −2.36,
t(33) = −3.89, p < 0.001), MDI total score (b = −1.24, t(33) = −3.70, p < 0.001), BDI-II total
score (b = −1.39, t(33) = −4.56, p < 0.001), and BAI total score (b = −1.33, t(33) = −4.25,
p < 0.001) also significantly decreased over time.
Table 6. Results of hierarchical linear models assessing the trajectory of changes in subjective
cognition and self-report symptom measures over time a .
CFQ Total Score
Effect

b

SE

t

df

p

d

Initial CFQ Severity (Intercept)
CFQ Severity Over Time (Slope)

53.90
−1.44

2.58
0.53

20.88
−2.72

33
33

<0.001
0.010

−0.47

PCL-5 Total Score
Effect

b

SE

t

df

p

d

Initial PCL-5 Severity (Intercept)
PCL-5 Severity Over Time (Slope)

43.13
−2.23

2.48
3.74

17.40
−5.97

33
33

<0.001
<0.001

−1.02

DERS Total Score
Effect

b

SE

t

df

p

d

Initial DERS Severity (Intercept)
DERS Severity Over Time (Slope)

103.02
−2.36

3.67
0.61

28.11
−3.89

33
33

<0.001
<0.001

−0.67

MDI Total Score
Effect

b

SE

t

df

p

d

Initial MDI Severity (Intercept)
MDI Severity Over Time (Slope)

55.95
−1.24

2.71
0.34

20.64
−3.70

33
33

<0.001
<0.001

−0.63

BDI-II Total Score
Effect

b

SE

t

df

p

d

Initial BDI-II Severity (Intercept)
BDI-II Severity Over Time (Slope)

28.07
−1.39

20.2
0.31

13.90
−4.56

33
33

<0.001
<0.001

−0.78

BAI Total Score
Effect

b

SE

t

df

p

d

Initial BAI Severity (Intercept)
BAI Severity Over Time (Slope)

25.12
−1.33

2.00
0.31

12.57
−4.25

33
33

<0.001
<0.001

−0.73

Note. CFQ = Cognitive Failures Questionnaire; PCL-5 = PTSD Checklist for DSM-5; DERS = Difficulties in Emotion
Regulation Scale; MDI = Multiscale Dissociation Inventory; BDI-II = Beck Depression Inventory II; BAI = Beck
Anxiety Inventory. a Unit of measurement in time is one week.
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The findings for the level 2 HLMs assessing the effects of baseline variables on the
trajectory of change in subjective cognition and self-reported symptoms over time are
presented in Table 7. Here, the DERS total score significantly influenced the trajectory of the
MDI total score over the duration of GMT, such that those with higher baseline DERS total
scores experienced significantly greater reductions in MDI total scores over time (b = −0.02,
t(30) = −2.11, p = 0.044). Similarly, the baseline BAI total score significantly influenced the
trajectory of the CFQ total score over time (b = −0.08, t(31) = −2.14, p = 0.041). Although
it did not reach the alpha level of significance of p = 0.05, an additional finding suggests
that the MDI total score may influence the trajectory of the CFQ total score over time
(b = −0.06, t(31) = −1.77, p = 0.087). Additional investigations of this trend within a more
robust sample size may be warranted in future studies. No other investigated level 2 HLMs
demonstrated significant findings.
Table 7. Results of hierarchical linear models assessing the impacts of baseline variables on the
trajectory of changes in subjective cognition and self-report symptom measures over time a .
Effect of Baseline PCL-5 on CFQ Total Score Trajectory
Effect

b

SE

t

df

p

d

Initial CFQ Severity (Intercept)
PCL-5 Total
CFQ Severity Over Time (Slope)
PCL-5 Total

48.49
0.57
−0.97
−0.04

2.30
0.15
0.59
−0.05

21.05
3.82
−1.65
−0.92

27
27
27
27

<0.001
<0.001
0.110
0.365

0.71
−0.31
−0.17

Effect of Baseline DERS on CFQ total score trajectory
Effect

b

SE

t

df

p

d

Initial CFQ Severity (Intercept)
DERS Total
CFQ Severity Over Time (Slope)
DERS Total

51.61
0.34
−1.25
−0.03

2.27
0.09
0.56
0.02

22.79
3.64
−2.25
−1.69

30
30
30
30

<0.001
<0.001
0.032
0.102

0.64
−0.40
−0.30

Effect of baseline DERS on PCL-5 total score trajectory
Effect

b

SE

t

df

p

d

Initial PCL Severity (Intercept)
DERS Total
PCL Severity Over Time (Slope)
DERS Total

40.14
0.41
−2.46
0.01

2.07
0.08
0.41
0.02

19.37
5.08
−5.98
0.39

30
30
30
30

<0.001
<0.001
<0.001
0.702

0.90
−1.06
0.07

Effect of baseline DERS on MDI total score trajectory
Effect

b

SE

t

df

p

d

Initial MDI Severity (Intercept)
DERS Total
MDI Severity Over Time (Slope)
DERS Total

54.04
0.36
−1.14
−0.02

2.28
0.10
0.28
0.01

23.73
3.72
−4.12
−2.11

30
30
30
30

<0.001
<0.001
<0.001
0.044

0.66
−0.73
−0.37

Effect of baseline DERS on BDI-II total score trajectory
Effect

b

SE

t

df

p

d

Initial BDI Severity (Intercept)
DERS Total
BDI Severity Over Time (Slope)
DERS Total

25.77
0.36
−1.47
−0.00

1.27
0.05
0.30
0.01

20.22
6.80
−4.89
−0.44

30
30
30
30

<0.001
<0.001
<0.001
0.664

1.20
−0.86
−0.08

Effect of baseline DERS on BAI total score trajectory
Effect

b

SE

t

df

p

d

Initial BAI Severity (Intercept)
DERS Total
BAI Severity Over Time (Slope)
DERS Total

22.60
0.34
−1.25
−0.02

1.61
0.06
0.33
0.01

14.01
5.45
−3.76
−1.63

30
30
30
30

<0.001
<0.001
<0.001
0.113

0.96
−0.67
−0.29
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Table 7. Cont.
Effect of baseline MDI on CFQ total score trajectory
Effect

b

SE

t

df

p

d

Initial CFQ Severity (Intercept)
MDI Total
CFQ Severity Over Time (Slope)
MDI Total

51.80
0.62
−1.25
−0.06

1.88
0.16
0.48
0.04

27.63
3.88
−2.63
−1.77

31
31
31
31

<0.001
<0.001
0.013
0.087

0.68
−0.46
−0.31

Effect of baseline BDI-II on CFQ total score trajectory
Effect

b

SE

t

df

p

d

Initial CFQ Severity (Intercept)
BDI Total
CFQ Severity Over Time (Slope)
BDI Total

52.73
0.73
−1.32
−0.02

2.23
0.14
0.52
0.04

23.63
5.36
−2.52
−0.586

31
31
31
31

<0.001
<0.001
0.017
0.562

0.93
−0.44
−0.10

Effect of baseline BAI on CFQ total score trajectory
Effect

b

SE

t

df

p

d

Initial CFQ Severity (Intercept)
BAI Total
CFQ Severity Over Time (Slope)
BAI Total

52.58
0.87
−1.31
−0.08

1.97
0.14
0.49
0.04

26.64
6.34
−2.66
−2.14

31
31
31
31

<0.001
<0.001
0.012
0.041

1.10
−0.46
−0.37

Note. PCL-5 = PTSD Checklist for DSM-5; CFQ = Cognitive Failures Questionnaire; DERS = Difficulties in Emotion
Regulation Scale; MDI = Multiscale Dissociation Inventory; BDI-II = Beck Depression Inventory II; BAI = Beck
Anxiety Inventory. a Unit of measurement in time is one week.

4. Discussion
The primary objective of this pilot RCT was to determine the effectiveness of GMT as
compared to a WL condition in improving objective and subjective cognition, functioning,
symptoms of PTSD, and symptoms associated with PTSD (i.e., difficulties with ER, dissociation, depression, and anxiety) in a sample of military personnel, veterans, and PSP. It was
hypothesized that those participants randomized to the GMT condition would experience
significant improvements in these outcomes relative to the WL condition. Generally, the
results of this pilot RCT support these hypotheses. Specifically, relative to participants
in the WL condition, participants in the GMT condition experienced significant improvements in areas of executive functioning, such as improvements in verbal fluency, planning,
impulsivity, cognitive shifting, and discrimination of targets. Collectively, the effect sizes
for these significant simple main effects ranged from medium to large, suggesting that the
effects of the GMT intervention may be replicated within a larger-scale RCT. Moreover, the
findings suggest that GMT may improve short-term declarative memory, as individuals in
the GMT condition demonstrated a trending improvement in their ability to recall words
from a list in comparison to those individuals in the WL condition. Future replications of
this study in a larger sample size may further elucidate this finding.
Notably, the significant improvements in objective cognition following the GMT intervention support previous research. For example, following completion of GMT, patients
diagnosed with obsessive compulsive disorder demonstrated significant improvements
in measures of problem-solving, planning, impulsivity, attention, and processing speed in
comparison to patients who were randomized to a WL condition [98]. In another study,
Boyd et al. (2019) demonstrated improvements on measures of executive functioning, planning, attention, and short-term declarative memory following a modified GMT protocol
for individuals receiving concurrent inpatient trauma treatment [99]. Similarly, the current
study found similar significant effects following the GMT intervention relative to the WL
condition in tasks of executive functioning (e.g., verbal fluency, impulsivity, cognitive
shifting, and discrimination of targets) and planning, as well as a trending improvement
in short-term declarative memory. Critically, the findings of the current pilot RCT also
demonstrate focused improvements in cognitive difficulties typically associated with PTSD,

Brain Sci. 2022, 12, 377

23 of 32

including executive functioning [26,29–32] and verbal learning, suggesting that GMT may
be an effective intervention to help address these concerns among military personnel,
veterans, and PSP with PTSD symptoms and symptoms associated with PTSD.
Although participants in the GMT condition did not experience significant improvements in their Stroop color, color–word, and interference scores relative to the WL condition,
these specific findings also help to demonstrate support that the GMT intervention may
improve executive functioning. GMT is designed to assist individuals with noticing attentional lapses and approaching tasks in a mindful manner, with the goal of reinstating
executive cognitive control when there is a discrepancy between the individual’s goal and
behaviour [59,89,128]. Given that the Stroop Color and Word Test instructs participants to
complete the tasks as quickly as possible within a time limit [110,111], the lack of improvements in these scores for those participants in the GMT condition suggests individuals
may have been more mindful while completing the task. Specifically, individuals in the
GMT condition may have been checking that their goal of completing the task accurately
matched with their behaviour, thereby slowing their response time, which subsequently
did not lead to score improvements. Relative to the individuals in the GMT condition, the
individuals in the WL condition did not receive such training and may have increased their
speed on this task given their familiarity with it during the post-intervention testing.
This purposeful slowing of response time while completing tasks may also explain
the significant increase in scores (i.e., worsening) for CPT 3.0 perseverations for those
individuals in the GMT condition. Perseverations may be attributed to slowed responses
to preceding stimuli, as well as random responses (e.g., errors), anticipatory responses (e.g.,
guesses), or repeated responses, suggesting impulsivity [114]. As impulsivity improved
following GMT (measured by the outcomes on the DKEFS Tower Test), the results of the
CPT 3.0 perseverations score suggests that participants in the GMT condition may have
slowed their responding. Subsequently, this may have caused individuals to miss the
original target and respond too quickly to the next target in the task. Alternatively, there
may be several other possibilities that may explain these findings, including anticipatory
responses, repeated responses, and that these cognitive functions may not demonstrate
significant change over the duration of the study trial. Subsequently, future research should
continue to explore these findings for additional clarification.
Improvements in the other neuropsychological measures may be attributable to practice effects. For example, although individuals in the GMT condition improved significantly
on TMT part B, the findings for those in the WL condition also demonstrated a trend towards score improvement. A similar trend was also observed on the WAIS-IV Digit Symbol
Coding Subtest, CPT 3.0 commissions, and CVLT Trial 5 Z scores. Practice effects may also
account for the improvements found on the DKEFS Tower Test rule violations measure
for those in the WL condition, which was not found among those participants in the GMT
condition. While there were no significant differences between the groups at baseline for
this measure, the maximum score for rule violations in the WL condition was higher at
baseline than the maximum score in the GMT condition (i.e., four errors versus two errors,
respectfully). At the subsequent follow-up testing appointment, those individuals in the
WL condition improved as they had a maximum score of two for rule violations, whereas
those participants in the GMT condition continued to have a maximum score of two for
rule violations. Consequently, this improvement in the WL condition’s rule violations may
be attributable to practice effects, as there was no intervention administered to this group
and their improvement in this measure may be attributable to their previous experience
and familiarity with the DKEFS Tower Test.
With respect to subjective cognition and self-reported functioning, participants in the
GMT condition also experienced significant improvements from pre- to post-testing in both
domains, whereas participants in the WL condition did not. Generally, PTSD is associated
with poorer social and occupational functioning [129,130], as well as reduced quality
of life [131]. More specifically, previous research has linked poorer subjective cognitive
functioning to higher levels of psychological distress [36,38,39], poorer functioning [38],

Brain Sci. 2022, 12, 377

24 of 32

and poorer quality of life [36,39,132] among individuals with PTSD. Previous research also
has found that objective measures of cognition are negatively associated with physical [40],
social, and occupational functioning [40,41] among military personnel and veterans with
PTSD. Considering this previous research, the current study’s findings demonstrate that
not only may GMT prove to be beneficial in assisting individuals’ objective and subjective
cognitive functioning, but also that these improvements in cognition may translate to
improvements in functioning for military personnel, veterans, and PSP. Future work should
aim to examine the specific domains of functioning (e.g., social, occupational, daily, etc.)
affected following participation in GMT, as well as whether quality of life also shows a
similar improvement following the GMT intervention. Additional studies should also aim
to examine whether GMT may be a useful intervention in assisting military personnel,
veterans, and PSP during return-to-work following a medical leave of absence due to PTSD.
Notably, this represents a significantly understudied area of clinical research as the factors
that contribute to a successful return to work for military personnel, veterans, and PSP
have remained largely unknown.
Improvements in psychological symptoms following participation in the GMT intervention relative to the WL condition were also found. Specifically, simple main effects
demonstrated that participants experienced improvements in PTSD symptom severity,
difficulties with ER, dissociative symptom severity, depressive symptoms, and anxiety
symptoms in the GMT condition, but not in the WL condition. These findings also demonstrated a medium to large effect size, suggesting again that these findings may be replicated
within a larger-scale clinical trial. These results may also suggest that along with improvements in objective and subjective cognitive difficulties, improvements in PTSD symptoms
and symptoms associated with PTSD may be indirectly targeted through a cognitive remediation intervention. This implies that GMT may be a useful adjunctive treatment for
individuals experiencing PTSD and its related psychological symptoms. Importantly, these
results support the use of a top-down cognitive remediation approach to address objective
and subjective cognitive difficulties, as well as PTSD and PTSD-related psychological symptoms. Top-down cognitive remediation targets higher-order neurocognitive abilities, such
as executive functioning, which can assist in the improvement of other cognitive functions
and in the generalization of these improvements to various contexts [59,89,133,134]. By
employing such an approach, the aim is to not only improve specific cognitive functions
but to also ameliorate any downstream dysfunction associated with the neural regions
and neural circuitry responsible for these cognitive functions. Specifically, indirect improvements in tasks of daily functioning and other psychological symptoms following the
implementation of a top-down cognitive remediation intervention were expected given
that previous studies have demonstrated similar findings [97,135]. Moreover, our results
support previous meta-analytic findings, which suggest GMT is associated with small to
medium improvements in objective and subjective measures of executive functioning, as
well as improvements in tasks of daily living and other mental health symptoms [97].
A secondary objective of the study was to examine the trajectory of self-reported
symptom change over the course of the GMT intervention for those individuals who were
initially randomized to the GMT condition, as well as those individuals in the WL condition
who elected to participate in GMT following their waiting period. Here, it was hypothesized
that the trajectory of symptoms would significantly decrease over time. Following level
1 HLM analyses, the results indicated that there were significant declines in self-reported
cognitive difficulties, as well as PTSD symptom severity, difficulties with ER, dissociative
symptom severity, depression symptom severity, and anxiety symptom severity. Notably,
these findings further support the assertion that GMT may be a useful adjunctive treatment
for PTSD, as well as for other psychological symptoms, given the significant decline in the
severity of these symptoms across time. Future studies are needed to elucidate whether such
symptom declines are comparable to those gained with current evidence-based treatments,
such as cognitive processing therapy and prolonged exposure therapy.
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Additional exploratory analyses were conducted to examine the effects of baseline
self-reported symptoms (e.g., subjective cognitive difficulties, PTSD symptoms, and other
psychological symptoms) on the trajectory of specific symptoms over time. Here, the results
demonstrated that difficulties with ER significantly influenced the trajectory of dissociative
symptoms across the GMT intervention, such that those participants with greater baseline
difficulties with ER experienced significantly greater reductions in dissociative symptoms
over time. Dissociative symptoms have been proposed as an ER strategy during and following traumatic events [15], as they allow individuals to detach from intense and distressing
emotions. Subsequently, these findings lend support to this established relationship, as
improvements in ER significantly influenced the trajectory of dissociative symptoms over
time. Moreover, this also supports the notion that individuals with more severe difficulties
with ER may still experience benefits from participating in GMT and that these symptoms
do not appear to interfere with other symptom improvements.
The analyses also explored whether baseline dissociative symptoms influenced the
trajectory of self-reported cognitive difficulties over the course of the GMT intervention.
Although these results did not reach the significance threshold (i.e., p = 0.05), they trended
towards significance. Notably, previous research suggests a strong relation between dissociative symptoms and cognitive functioning [33–35,136], such that increased dissociative
symptom severity is associated with heightened difficulties with verbal memory [34], visual
memory [34,35], attention [35], executive functioning, and autobiographical memory. Further
studies involving larger sample sizes are required to confirm the specificity of these effects.
Additional analyses examined whether baseline anxiety symptom severity influenced
the trajectory of subjective cognitive difficulties over the course of the GMT intervention.
Notably, these results were significant, such that those participants who began the GMT
intervention with higher anxiety scores showed greater reductions in subjective cognitive
difficulties over the duration of GMT. Numerous studies document the relation between
anxiety and cognitive difficulties, where anxiety symptoms, such as worry, can impair
executive functions such as problem-solving [137] and inhibition [138,139], as well as impair
attention [140] and working memory [138]. Clinician-rated severity of difficulties with
concentration associated with anxiety symptoms appears further to mediate the relation
between subjective reports of worry and clinician-rated severity of anxiety symptoms [141].
Here, it is thought that anxiety increases cognitive demand, thereby interfering with
other cognitive functions, including executive functioning and attention [142–144]. In line
with previous work, the current findings suggest that improvements in reported anxiety
symptoms reduce subjective cognitive difficulties over time.
Exploratory analyses also examined the effects of baseline symptoms on the trajectory
of change in subjective cognition, as well as the severity of other psychological symptoms.
Specifically, we examined whether difficulties with ER influenced the trajectory of selfreported cognitive difficulties, as well as PTSD, depression, and anxiety symptom severity.
We also explored whether PTSD symptom severity and depression symptom severity influenced the trajectory of self-reported cognitive difficulties. No such relations emerged. These
findings were somewhat unexpected given the reported associations between difficulties with
ER and cognitive dysfunction [15,50,51,60–62], difficulties with ER and psychological symptoms [10,16,17,145], PTSD symptom severity and self-reported cognitive difficulties [28,32],
and depression and self-reported cognitive difficulties [146]. Additional research with a
larger sample is clearly warranted. This work is ongoing in our laboratory.
The results of the study must be interpreted with caution. As this is a pilot study, it
involved a relatively small sample size. The large number of analyses conducted may have
increased the probability of type I error leading to erroneous conclusions. To mitigate this
potential error, the analyses chosen were based on previous findings within the literature
and specific hypothesis were explored. Analyses also were limited to pre- and postintervention to ensure the retention of the largest possible sample size. An additional
limitation of the study is that the ANOVA analyses were followed up with simple main
effects, not only when there were significant interactions, but also if there were significant
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main effects or inspection of the effect sizes and means and SDs between the GMT and
WL conditions suggested further exploration. Accordingly, despite very promising signals,
the results of the study should be interpreted with caution. Analyses also were conducted
on data in which there were several violations of homogeneity of variance and normality.
Transformation of these data did not improve the normality or homogeneity of variance,
and parametric analyses were conducted on the non-transformed variables.
With respect to the study design, the repeated use of certain neuropsychological
assessment measures (e.g., DKEFS Tower Test, WAIS-IV Digit Symbol Coding Subtest, TMT,
etc.) may have positively influenced the test outcome due to practice. Where appropriate,
outcomes which may be attributable to practice effects were indicated. Critically, these
practice effects would be expected to be equivalent across the active treatment and wait-list
groups. An additional limitation of the study design is that individuals could have been
administered the same self-report measures as those in the GMT condition during the WL
condition’s nine-week waiting period. Doing so would have allowed for comparisons
between the WL and the GMT conditions using HLM analyses. Future work should
consider implementing this methodology.
A strength of this study, however, was its status as an effectiveness pilot RCT designed
to be inclusive of participants with a spectrum of PTSD and co-morbid psychological
symptoms to mimic the diversity of symptom presentation found within clinical settings.
This factor coupled with the strong study findings suggest that improvements associated
with GMT may generalize to military personnel, veterans, and PSP seen under real-world
conditions with varying symptom severity of PTSD and other psychological comorbidities
and symptoms. Future work should aim to replicate these findings within a larger sample
size to determine whether these preliminary findings regarding the effectiveness of GMT
continue to hold. A larger sample size would allow analyses to determine the durability
of these findings. Future research may also compare GMT to an active WL condition (e.g.,
psychoeducation group discussing brain and cognitive changes associated with PTSD; this
work is underway in our laboratory). This design would assist in determining whether
GMT or the process of being in a treatment group with clinicians and other group members
with similar symptoms contributes to the improvements found following participation
in the GMT intervention. Finally, given that GMT targets objective cognitive difficulties
and that PTSD is associated with alterations in cognitive functioning that may stem from
altered neural functioning and circuitry, it would be helpful to conduct a RCT that includes
neuroimaging pre- and post-treatment and in comparison, to a matched control condition.
This design would allow us to assess any functional or structural brain changes associated
with participation in GMT.
5. Conclusions
On balance, this pilot RCT is the first to examine whether GMT is an effective cognitive
remediation intervention among military personnel, veterans, and PSP with symptoms of
PTSD and co-symptoms commonly associated with this condition. The findings of the study
suggest that not only do objective and subjective measures of cognition improve following
GMT, but also that functioning and symptoms of PTSD, difficulties with ER, dissociation,
depression, and anxiety also show improvement. Given that cognitive difficulties persist for
approximately 25% of patients following treatment of PTSD [46], as well as the devastating
functional impacts associated with PTSD and cognitive dysfunction [40,41], these findings are
promising, suggesting the potential utility of GMT as an adjunctive treatment for this condition.
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